Although Alzheimer's Disease (AD) is the most common cause of dementia, the pathogenic mechanisms are not yet fully understood and disease-modifying therapy is not yet available. Very early and accurate diagnosis will clearly be needed to achieve the best treatment outcomes. Over the past decade, the introduction of specific biomarkers such as cerebrospinal fluid (CSF) proteins and functional neuroimaging into the diagnostic criteria has driven major changes in our understanding of AD. New classifications have been developed (e.g. the ATN system) and AD is now viewed as a biological entity rather than a clinical one. Some interesting new biomarkers are currently under investigation with the aim of ameliorating both diagnostic and prognostic accuracy. These include neurofilaments or synaptic-related proteins such as neurogranin, synuclein, and synaptosomal-associated protein (SNAP). In addition, AD-associated proteins such as amyloid and tau can be investigated in tissues other than CSF that are easier to collect, such as blood and saliva. Furthermore, novel neuroimaging tracers are being developed to detect in vivo deposition of tau, or neuroinflammation of the brain.
The goal of the current special issue is to gather original research, communications and reviews to further clarify the role of biomarkers in the diagnosis and prognosis of AD.
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- The Role of CSF Transthyretin in Human Alzheimer's Disease: Offense, Defense, or not so Innocent BystanderJoel N. BuxbaumJ. Integr. Neurosci. 2023, 22(6), 158; https://doi.org/10.31083/j.jin2206158(This article belongs to the Special Issue Diagnostic and Prognostic Biomarkers for Alzheimer’s Disease)12Downloads74Views